NOVARTIS-CEMA401A2201

Study Sponsor: Novartis

Study Title

A double-blind, placebo-controlled, randomized dose ranging trial to determine the safety and efficacy of three dose levels of EMA401 in reducing 24-hour average pain intensity score in patients with post-herpetic neuralgia

Medicine or Vaccine (generic name)

olodanrigan

Sponsor Identification Number

CEMA401A2201

Trial Registry Identification Number(#'s)

NCT03094195

Medical Condition

Postherpetic neuralgia (PHN)

Phase

Phase 2

Link to study details on the Novartis Clinical Study Register

https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17628

Link to study details on ClinicalTrials.gov (if available)

https://www.clinicaltrials.gov/ct2/show/NCT03094195?term=CEMA401A2201&rank=1

Link to study details on EudraCT (if available)

https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000280-16

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

Date Added to this Site

June 2020